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This study, in optimally treated CAD patients with newly diagnosed OSA, focused on (1) The
relationships between OSA and serum biomarkers of four potential pathways of cardiovascular
injury in OSA: high-sensitivity C-reactive protein (hs-CRP), endothelin-1 (ET-1), N terminal pro
B type natriuretic peptide (NT-proBNP) and fibrinogen; and (2) The effect of continuous posi-
tive airway pressure (CPAP) therapy on these markers.
151 Chinese patients with proven CAD and standard medication were enrolled. After poly-
somnography, patients were classified into four groups according to apneaehypopnea index
(AHI): no OSA (n Z 25); mild OSA (n Z 50); moderate OSA (n Z 43); severe OSA (n Z 33).
Morning levels of hs-CRP, ET-1, NT-proBNP and fibrinogen were assayed and repeated in severe
OSA patients after 3-months CPAP treatment.
Hs-CRP was greater in patients with severe OSA than those with no OSA or mild OSA
(P Z 0.001, P Z 0.003; respectively). After adjustment for confounders, the hs-CRP levels
correlated most strongly with AHI and oxygen desturation index (ODI) (r Z 0.439,
P < 0.001; r Z 0.445, P < 0.001; respectively). In stepwise multiple linear regressions, the
strongest predictor of hs-CRP levels was ODI (P < 0.001). After 3 months of CPAP treatment,
the hs-CRP levels deceased (P Z 0.005) in CAD patients with severe OSA.
In CAD patients on current optimal medications, hs-CRP is significantly correlated with the
severity of OSA, and the elevated hs-CRP levels can be decreased by CPAP. This suggests that
OSA could activate vascular inflammation in CAD patients despite current best practice medi-
cations.
ª 2011 Elsevier Ltd. All rights reserved.88398196; fax. þ86 10 88396589.
com (Z.-h. Liu).
1 Elsevier Ltd. All rights reserved.
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18 (4) Normal routine laboratory screening resultsObstructive sleepapnea (OSA) is amajor public healthhazard
affecting 3e5% of the adult population.1,2 Increasing
evidence is emerging that OSA is a risk factor for coronary
artery disease (CAD).3 Middle-aged patients with untreated
OSA are at high risk of developing coronary artery disease.4
Patients with established coronary artery disease have
a high prevalence of sleep disordered breathing,5,6 and the
long-term prognosis is poor in patients with both CAD and
untreated OSA.7,8 New cardiovascular events reduced in CAD
patients who had co-existing OSA and accepted sleep apnea
treatment versus those who refused treatment.9
While definitive proof of a causal link between OSA and
CAD awaits the results of well-designed randomized
controlled trials of OSA treatment, there is considerable
uncertainty about which patho-physiological mechanisms in
OSA might mediate vascular injury and CAD progression.10 A
number of neural and humoral abnormalities including
sympathetic activation, vascular endothelial dysfunction,
inflammation, abnormal coagulation and metabolic dys-
regulation,11e17 have been reported in patients with OSA
which may be implicated in the initiation and progression of
cardiovascular diseases. However, whether continuous
positive airway pressure (CPAP) treatment for OSA could
inhibit the putative pathways of vascular injury remains
controversial.
The present study, to our knowledge, is the first study to
assess the relationship of OSA with various biomarkers of
cardiovascular risk in Chinese subjects with optimally
treated CAD. In this way we sought to determine which
pathways were most strongly associated with OSA and
might therefore warrant further evaluation for CAD
secondary prevention in the future. In the first part, we
conducted a cross-sectional analysis examining the rela-
tionship between OSA severity and four key biomarkers: (1)
endothelin-1 (ET-1), a marker of endothelium dysfunction,
(2) high-sensitivity C-reactive protein (hs-CRP), a marker of
inflammation, (3) N terminal pro B type natriuretic peptide
(NT-proBNP), a marker of ventricular strain, and (4) fibrin-
ogen, a marker of hyper-coagulation. We next evaluated
the effect of CPAP treatment on these biomarkers in CAD
patients with severe OSA.MethodsPatient selection
The study was approved by the Human Ethics committee of
Fuwai Hospital and all patients gave their written informed
consent. Consecutive CAD patients were recruited from the
fifth inpatient department of the Fuwai Hospital, from
March 2008 to June 2010.
Inclusion criteria
(1) Men and women aged between 25 and 80 years; (2) CAD
verifiedby coronary angiography (either70% stenosis in one
major coronary artery or50% stenoses in two ormoremajor
coronary arteries); (3) On appropriate medications for at
least 3 months for CAD risk reduction as per AHA/ACCincluding white cell count, serum electrolytes, glucose,
thyroid-stimulating hormone (TSH) and urinary albumin.
Exclusion criteria
(1) predominantly central sleep apnea; (2) heart failure
with New York Heart Association Functional Classification
ⅢeⅣ; (3) pulmonary diseases causing dyspnea at rest or on
minimal exertion; (4) plasma alanine aminotransferase
(ALAT) > 200 U/L; (5) chronic inflammatory disorders such
as rheumatoid arthritis or inflammatory bowel disease; (6)
plasma creatinine >200umol/L; (7) acute cerebrovascular
insult within 3 months; (8) history of drug abuse; (9) preg-
nancy; (10) history of blood donation less than 1 month
before entry into the study; or (11) previous treatment with
CPAP. If patients had suffered from an acute systemic
inflammatory process such as infection, trauma, or infarc-
tion, blood sampling was delayed until the patient had
made a full recovery.
Sleep studies
All patients underwent overnight Type 3 polysomnography
(PSG) in the Sleep Center of Fuwai Hospital using an Embletta
recording device (Embletta 9, Medcare Flaga, Reykjavik,
Iceland) which recorded nasal airflow (with an oro-nasal
thermistor), finger pulse oximetry, thoracic and abdominal
movement, body position and snoring. The PSG device was
programmed to begin recording at the patient’s usual
bedtime and was turned off at the time of the patient’s final
morning awakening. All polysomnography data were manu-
ally scored using standard criteria19 by a sleep technician,
who was blinded to the clinical characteristics of the
patients. Hypopnea was defined as more than 50% reduction
in nasal airflow for 10 s which was accompanied by a 4%
fall in artery oxygen saturation (SaO2). Apnea was defined as
a cessation in airflow for 10 s.
The apnea-hypopnea index (AHI) was calculated as the
total number of respiratory events (apneas plus hypopneas)
per hour of overnight recording. Patients were divided into
one of four groups depending on their AHI: no OSA (AHI <5
events per hour), mild OSA (AHI 5 to <15), moderate OSA
(AHI 15 to <30), and severe OSA (AHI30). Other PSG
variables included oxygen desturation index (ODI), mean
SaO2, minimal SaO2, and percentage of time with
SaO2<90%. The Epworth Sleepiness Scale (ESS) was used to
measure changes in subjective daytime sleepiness.20
Blood samples
In the morning (between 6:00 AM and 6:30 AM), fasting
blood samples were drawn from an antecubital vein and
collected in appropriate tubes for different measurements.
Samples were placed immediately on crushed ice, and
centrifuged within 10 min of collection. The supernatant
plasma or serum was drawn off and kept in a refrigerator at
80 Celsius for assay. Plasma ET-1 was measured using
a commercial, highly sensitive and specific sandwichen-
zyme immunoassay (Biomedica, Wien, Austria). Serum
hs-CRP was measured using particle enhanced immunone-
phelometry (Dade Behring, nc. Deerfield, Illinois). Plasma
Effects of OSA and CPAP on CAD patients 1559NT-proBNP levels were measured using an enzyme immu-
noassay kit (BIOMEDICA, GmbH, Germany). Fibrinogen and
other biochemical factors were measured by routine
enzymatic method. All samples were processed by techni-
cians blinded to the clinical condition of the patients.
CPAP treatment
CAD patients with severe OSA were offered treatment with
CPAP. They were prescribed fixed-level CPAP which corre-
sponded to the 95th centile pressure recorded during
a single night of in-laboratory pressure titration using an
automated pressure setting device (S7 Autoset-T, ResMed,
Sydney, Australia), and patients were supplied with a CPAP
generator (S6, ResMed, Sydney, Australia) for home use. All
the patients were followed-up at three months at which
CPAP adherence and AHI were recorded from the machine
microprocessor, and repeat fasting blood samples were
obtained and processed using the same method at the
baseline for the investigational biomarkers as well as serum
lipids and fasting blood glucose.
Statistical analysis
Statistical analyses were performed on SPSS for Windows,
version 16 (SPSS Inc, Chicago, IL). Quantitative variables
were expressed as mean  standard deviation (SD) after
checking normality with the KolmogoroveSmirnov test. The
chi-square test was used to compare categorical data. The
significance of differences between 2 groups was analyzed
with Student’s t test. Differences in variables among the 4
groups were evaluated by analysis of variance (ANOVA) and
a Boneronni correction was applied for multiple compari-
sons. Relationships between the level of NT-proBNP,
fibrinogen, hs-CRP, ET-1 and baseline characteristics were
assessed using Pearson correlation coefficient for contin-
uous variables and Spearman correlation coefficient for
categorical variables. Both unadjusted and adjusted (for
conventional risk factors, such as sex, age, BMI, smoking
and drinking status, diabetes mellitus, hypertension, lipid
profiles, fasting blood glucose, and medication) associa-
tions were calculated to identify variables that were
independently associated with the four biomarkers. Multi-
variate linear regression analysis using a stepwise selection
of the explicative variables was undertaken. A value of
p < 0.05 was considered statistically significant.
Results
Characteristics of the study population
Of 178 consecutive patients who met the selection criteria
for CAD and underwent PSG in the sleep lab, 27 were
subsequently excluded because of the following conditions:
previous stroke, liver damage, or renal dysfunction (12);
recent surgery (1); prior CPAP therapy for sleep disordered
breathing (1); failure to comply with recommended statin
and anti-platelet medicine (aspirin) (13). This left 151
subjects who were considered suitable for blood biomarker
measurements.Table 1 shows the anthropomorphic data, PSG results,
and clinical characteristics of the study population divided
into the four OSA severity groups. Twenty-five patients
were found to have no OSA, 50 had mild OSA, 43 had
moderate OSA, and 33 had severe OSA. Thus of the 151 CAD
patients, 83% had OSA and 50% had moderate to severe
OSA. There was a marked male predominance of patients in
all four categories. As expected, average BMI was signifi-
cantly higher in the more severe OSA groups.
Levels of hs-CRP were significantly higher in patients
with severe OSA (4.29  3.49 mg/L) than patients with no
OSA (1.95  1.16 mg/L, PZ 0.003) or in patients with mild
OSA (2.07  1.91 mg/dL, PZ 0.001; Table 2, Fig. 1). There
were no between group difference in the levels of the other
biomarkers of cardiovascular risk.
Correlation between OSA severity and biomarkers
of cardiovascular risk
Pearson correlation coefficients of PSGvariableswith clinical
parameters and investigational biomarkers are given in
Table 3. The hs-CRP correlated most strongly with AHI, ODI,
minimal SaO2 and percentage of time with SaO2<90%
(r Z 0.439, P < 0.001, Fig. 2; r Z 0.444, P < 0.001;
rZ 0.250, PZ 0.001; rZ 0.177, PZ 0.03; respectively).
These correlations remained essentially unchanged after
adjustment for confounders. Adjusted correlations between
hs-CRP and AHI, ODI, and minimal SaO2 were: r Z 0.439,
P < 0.001; r Z 0.445, P < 0.001; r Z 0.249, P Z 0.003,
respectively.
Stepwise multiple linear regression was used to evaluate
the relative strength of association, between hs-CRP and
OSA severity (AHI, ODI) as well as the other possible
confounders. The strongest predictor of serum hs-CRP levels
was ODI (P < 0.001), followed by age (P Z 0.005) and sex
(P Z 0.018). Indices that reflect the intermittent nature of
the breathing and gas exchange disturbance (e.g. AHI)
appeared to be more strongly associated with increased hs-
CRP than parameters of SaO2 (e.g. time with SaO2<90%).
None of the PSG variables correlated with the levels of
NT-proBNP, ET-1 or fibrinogen in univariate analyses. NT-
proBNP was, however, strongly correlated with age
(r Z 0.193, P Z 0.009) although this association was
weaker (r Z 0.147, P Z 0.05) after adjustment for
confounders. In multiple linear regression, only age was
found to be was significantly correlated with the NT-proBNP
levels (R Z 0.193, P Z 0.018). In univariate analyses,
clinical parameters that significantly correlated to ET-1
were age (P Z 0.015). However, in both Pearson’s corre-
lation and stepwise multivariate analysis, there was no
reliable predictor for the ET-1 levels. The levels of fibrin-
ogen had no significant relationship with all these related
clinical factors.
Effects of CPAP on biomarkers of cardiovascular
risk in patients with severe OSA
Thirty three consecutively recruited CAD patients with
severe OSA were offered CPAP treatment. Four patients
declined CPAP treatment after titration and two patients
had very poor compliance (i.e. less than 1 h per day). The
Table 1 Baseline Characteristics of CAD Patients in the four OSA groups.
No OSA Mild OSA Moderate OSA Severe OSA P value
No. of patients 25 50 43 33
Sex, Male/Female 20/5 45/5 38/5 27/6 0.515
Age, years 56.1  9.3 57.7  11.1 57.6  10.5 63.2  12.3 0.053
BMI, kg/m2 25.5  2.3 26.2  2.5 27.3  3.3 28.2  2.8 0.001
AHI, events/h 2.7  1.5 9.5  3.0 20.6  4.2 47.3  15.8 <0.001
ODI (4%), events/h 3.5  2.0 9.7  3.4 21.0  5.4 46.4  16.2 <0.001
Mean SaO2, % 93.5  1.7 90.0  7.8 92.8  1.8 90.2  5.5 0.384
Minimum SaO2, % 87.7  3.0 80.4  7.2 80.8  5.5 71.2  12.5 <0.001
SaO2<90% (%TST) 2.9  6.0 5.6  11.2 9.4  13.5 27.0  29.1 <0.001
Traditional cardiovascular risk factors
Smoker 16(64.0%) 34(68.0%) 25(58.1%) 16(48.5%) 0.336
Alcohol consumption 6(24.0%) 27(54.0%) 20(46.5%) 9(27.3%) 0.022
Hypertension 14(56.0%) 29(58.0%) 33(76.7%) 25(75.8%) 0.103
Diabetes mellitus 2(8.0%) 18(36.0%) 15(34.9%) 14(42.4%) 0.033
Hyperlipidemia 6(24.0%) 10(20.0%) 7(16.3%) 7(21.2%) 0.884
Medications
Beta-blockers 23(92.0%) 41(82.0%) 40(93.0%) 29(87.9%) 0.372
ACE inhibitors 15(60.0%) 34(68.0%) 36(83.7%) 23(69.7%) 0.163
CCB 13(52.0%) 30(60.0%) 24(55.8%) 23(69.7%) 0.521
Abbreviations: ACE inhibitors, angiotensin-converting enzyme inhibitors; AHI, apnoea-hypopnea index; ALAT, alanine aminotransferase;
BMI, body mass index; CCB, calcium channel blockers; ODI, oxygen desaturation index; SaO2, artery oxygen saturation.
SaO2<90% (%TST) Z % of total sleep time with oxygen saturation<90%.
Values are expressed as mean  s.d. or n (%).
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a mean compliance of 4.9 þ 1.2 h per day. CPAP treatment
decreased the AHI (47.81  11.30 to 3.49  1.28 events/hr,
P < 0.0001) and ESS value (10.67  2.81 to 6.00  2.68,
P < 0.001). There was no change in the BMI (27.51  3.08 to
27.25  3.07, P Z 0.792) and no new cardiovascular
diseases or infectious diseases were detected during the
follow-up period.
CPAP significantly decreased hs-CRP (4.18  3.26 to
2.27  2.42 mg/L, P Z 0.005; Fig. 3). Changes in AHI after
treatment with CPAP were positively correlated with
changes in levels of hs-CRP (r Z 0.546, P < 0.01) and ESS
(r Z 0.652, P < 0.01). However, none of the other
biomarkers, lipid profiles or glucose changed after 3 months
of CPAP treatment.Table 2 Biochemical factors in CAD patients divided into four
No OSA Mild OSA
hs-CRP, mg/L 1.95  1.6 2.07  1.9
Endothelin-1, fmol/mL 0.61  0.16 0.78  0.9
NT-proBNP, fmol/mL 816.7  492.3 751.3  43
Fibrinogen, g/L 4.09  0.87 3.79  0.7
Triglyceride, mmol/L 1.83  0.88 2.08  1.3
TC, mmol/L 4.53  1.19 4.34  1.0
HDLC, mmol/L 1.11  0.32 1.13  0.3
LDLC, mmol/L 2.52  1.05 2.21  0.8
Fasting glucose, mmol/L 5.41  1.17 6.19  1.9
Abbreviations: HDLC, high-density lipoprotein cholesterol; hs-CRP, h
cholesterol; NT-proBNP, N terminal pro B type natriuretic peptide; TC
Values are expressed as mean  s.d.Discussion
The current study suggested that in Chinese patients with
CAD on current optimal medications, the levels of hs-CRP
were significantly and independently correlated with the
severity of OSA, and the elevated hs-CRP levels can be
decreased by CPAP treatment supporting an independent,
causal relationship between OSA and systemic inflammation.
These results are consistent with a several previous
reports.21e23 The observed correlation between AHI and hs-
CRP levels was also found by Boudjeltia et al21 demon-
strating that AHI is an independent predictor of hs-CRP
elevation. However, they did not take ODI as a confound-
ing factor. A recent study showed significant decreases in
the levels of hs-CRP in OSA patients after 6-months CPAPcategories of OSA severity.
Moderate OSA Severe OSA P value
1 2.95  2.61 4.29  3.49 <0.001
2 0.71  0.33 0.67  0.24 0.664
3.0 857.4  431.1 940.2  657.4 0.530
9 3.91  0.73 4.33  0.74 0.058
9 1.90  1.17 1.73  0.83 0.564
5 4.19  1.09 4.11  1.03 0.446
8 1.10  0.31 1.05  0.23 0.711
4 2.23  0.83 2.21  0.88 0.484
2 5.64  1.38 6.30  1.88 0.110
igh-sensitivity C-reactive protein; LDLC, low-density lipoprotein
, Total cholesterol.
Figure 1 Serum levels of hs-CRP in control subjects (n Z 25), patients with mild OSA (n Z 50), patients with moderate OSA
(n Z 43), and patients with severe OSA (n Z 33).
Effects of OSA and CPAP on CAD patients 1561treatment with good compliance, compared with poor
compliance group and those who refused CPAP treatment.22
On the other hand, not all previous reports have reported
such a relationship or shown changes with CPAP. Dorkova
et al24 failed to find significant changes in hs-CRP levels
after 8 weeks of CPAP therapy, whereas reduction in tumor
necrosis factor-a which is also a marker of inflammation
were observed.
In contrast to previous studies25e29 we could find no
association between the other biomarkers of ET-1, NT-
proBNP or fibrinogen. One important explanation might be
that previous studies focused on OSA patients who were
free of other diseases and were taking no medications. The
medications for CAD are known to effect the expression of
these biomarkers. The current study suggest that these
medications might suppress or reverse any tendency for
OSA to induce endothelial dysfunction, left ventricular
strain or hyper-coagulopathy, but apparently not OSA-Table 3 Pearson’s correlation of PSG variables with clinical me
AHI
correlations (P value)
ODI
correlations (P value)
Mean
corre
Age 0.234(0.004) 0.233(0.004) 0.1
BMI 0.308(<0.001) 0.308(<0.001) 0.0
hs-CRP 0.439(<0.001) 0.444(<0.001) 0.1
Endothelin-1 0.044(0.59) 0.033(0.691) 0.0
NP-proBNP 0.105(0.197) 0.092(0.260) 0.1
Fibrinogen 0.114(0.198) 0.114(0.197) 0.0
For definition of abbreviations, see footnote to Tables 1 and 2.induced systemic inflammation. There may be other
reasons why levels of ET-1, NT-proBNP, and fibrinogen were
not significantly correlated with PSG variables in our study.
Gjørup et al. found that the mean nocturnal level of ET
correlated significantly to the apneaehypopnea index
(AHI).27 The biased results of ET-1 with the previous studies
might due to the short half-life of endothelin-1 whose
activity is difficult to measure in vivo. Previous study
reported elevated levels of NT-proBNP in school-aged chil-
dren with OSA,28 however, most studies failed to identify
such an association.30,31 The role it played between OSA
and CAD needed to be further assessed.
Hs-CRP is a biomarker of inflammation. To date no better
marker has been found to replace hs-CRP as a marker of
inflammation and atherosclerosis. Statin therapy is an
important medication for CAD patients, and has the dual
effect of both regulating blood lipids and reducing levels of
hs-CRP. Fifty-four prospective cohort studies have shownasurements and investigational biomarkers.
SaO2
lations(P value)
Minimum SaO2
correlations(P value)
SaO2 <90%
correlations(P value)
59(0.049) 0.192(0.017) 0.281(<0.001)
14(0.859) 0.092(0.26) 0.202(0.012)
45(0.076) 0.25(0.002) 0.177(0.03)
21(0.785) 0.012(0.877) 0.018(0.821)
42(0.081) 0.023(0.779) 0.013(0.878)
69(0.432) 0.089(0.313) 0.072(0.413)
Figure 2 Correlation between serum levels of hs-CRP and AHI.
1562 Q. Zhao et al.that hs-CRP is a strong independent predictor of risk of
future myocardial infarction, stroke, and vascular death,
regardless of the LDL cholesterol level.32e34 The JUPITER
study35 was the largest one to evaluate the role of hs-CRP.
In apparently healthy persons without hyperlipidemia butFigure 3 Effect of CPAP on serum levels of hs-CRP in patients wi
with CPAP for 3 month. Changes in levels of hs-CRP before and aftwith elevated hs-CRP levels, statin treatment significantly
reduced the incidence of major cardiovascular events. It
also suggested that elevated hs-CRP levels rather than
elevated LDL cholesterol levels had greater effects on the
prognostic prediction. Therefore, for patients who haveth severe OSA (nZ 27). Patients with severe OSA were treated
er treatment with CPAP were demonstrated.
Effects of OSA and CPAP on CAD patients 1563already suffered from cardiovascular disease, especially
CAD, the percent fall in hs-CRP level may be a very useful
marker of how successful the secondary prevention for CAD
is likely to be.
In this study, with moderate dose statin therapy the
levels of lipids were not related to the severity of OSA,
however hs-CRP levels were still significantly correlated
with OSA severity. One conclusion that might be drawn is
that standard doses of statin cannot satisfactorily control
the levels of hs-CRP in CAD patients with OSA, especially
those with severe OSA. Thus OSA may induce further
cardiovascular events through activating vascular inflam-
mation in CAD patients, even in those who are optimally
treated with standard medications. CPAP treatment in
patients with CAD and severe OSA may therefore be good
secondary prevention treatment.
There are some limitations in the current study. Firstly,
we did not use a randomized placebo-controlled trial design
to test the effects of CPAP. Regression to the mean or
a sustained drug effect might theoretically therefore
account for the findings. The other limitation of the current
study is that different kinds of statins were used in the CAD
patients. Focusing on one statin might result in more con-
vincible data. However, these statins in the present study
are all used in moderate doses, which remains the question
whether the relationship between OSA and hs-CRP still exist
with statins in intensive doses. Future large-scale,
randomized placebo-controlled OSA treatment studies are
needed to assess the roles OSA and inflammation play in the
progression of CAD. Future studies evaluating the effects of
statin on hs-CRP should take account of OSA as a potential
confounding factor.
In conclusion, our study shows that hs-CRP is positively
correlated with the severity of OSA in CAD patients who are
taking standard medications for secondary cardiovascular
risk reduction. It also suggests that elevated hs-CRP levels
can be decreased by CPAP. It will be important in future
studies to determine whether elevated hs-CRP levels in CAD
patients suffering from OSA are indicative of increased risk
of future adverse cardiovascular events, and whether CPAP
or other therapies specifically targeting the inflammatory
pathways implicated in atherogenesis can reduce that risk.Conflict of interest statement
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